ATAREAL (Antihistamine Treatment for Allergic Rhinitis in Real Life)

A Pilot, Open, Monocenter, Randomized Two Parallel Groups, Clinical Efficacy Trial: Comparison Continuous Versus on Demand Regimen of Treatment With Levocetirizine 5 mg Oral Tablets, Once a Day, in Adults Suffering From Persistent Allergic Rhinitis (PER) Over 6 Months

Comparison of clinical efficacy and safety of levocetirizine in PER continuous versus on demand, measured by evolution of individual symptom scores during 6 months.

Inclusion Criteria:

• Clinical history of Persistent allergic Rhinitis (PER) requiring treatment known at least since 2 years.
• Positive skin prick test (wheal > 3 mm larger than the diluent control) or Radio Allergo Sorbent Assay (RAST) (>= 3.5 IU/ml) to House Dust Mite (HDM) and Parietaria (less than 1 year).
• Minimum mean Total 4 Symptom Score (T4SS) of 6 over baseline period.

Exclusion Criteria:

• Subjects currently treated by specific parietaria pollen immunotherapy
• Subjects suffering from non-allergic asthma
• Chronic use of inhaled steroids and/or long acting β2 agonists; and/or corticosteroids dependent asthma (severe asthma)
• Atopic dermatitis or urticaria requiring antihistamine treatment or the administration of oral or topical corticosteroids